top of page

"Question the protocol": Western Blotting close to the Patient

Nov 5
7 min read

Updated: Nov 10

An interview with Glenda Alquicer, PhD, research scientist at the Department of Experimental Rheumatology, Institute of Rheumatology, Prague


After twenty years at the bench, Glenda Alquicer is working, for the first time, directly with the disease she studies. At the Institute of Rheumatology in Prague, she grows cells from patients’ synovial tissue and tests nanoparticle-delivered drugs and cannabinoid receptor agonists on them — with each patient’s full treatment history at hand. We spoke with her about how a clinical sample becomes a research result, why low-abundance and phosphorylated proteins push Western blotting to its limits, the detergent that quietly sabotaged an inherited protocol, and what she expects from the tools on her bench.



Let’s start with your background. What brought you to the Institute of Rheumatology, and what does your work there involve?

G: I’ve worked at the Institute of Rheumatology for three years as a research scientist. My background is in biology, and I later specialised in physiology through my master’s and PhD. My work is basic research on proteins — specifically, biomarkers related to rheumatoid pathologies. We try to detect them, quantify them and understand some of their underlying biology, which is why the department is called Experimental Rheumatology.

I’m currently involved in several projects: one on nanoparticles that carry drugs to help treat rheumatoid arthritis, one testing cannabinoid receptor agonists, and a couple of newer projects that are still being set up. Day to day, my work includes Western blots, ELISA and a lot of other immunoassays, plus working with cell cultures to study these molecules.

 

Your institute combines a clinic with a research laboratory. How does a patient sample travel from the doctor’s office to your bench?

G: Doctors at the institute see the patients directly — they know the treatment history, the duration of the illness and the symptoms. Samples (blood, sometimes tissue, sometimes imaging) then go to the biochemistry department for standard measurements. Our department, the experimental side, takes samples such as serum (separated from clotted blood), plasma or urine, and measures rheumatic disease biomarkers directly in them.

This is also how our collaborations work: the Faculty of Pharmacology provides cannabinoid agonists and antagonists or nanoparticles, and we test them directly on patient-derived samples, always with the patients’ informed consent[ABGP1]  and the ethical commission’s approval. Personally, I grow cells from synovial tissue collected from patients and then apply different stimulations — for example, testing how a nanoparticle delivers its drug in vitro.

“In twenty years of my career, this is the first time I’ve been able to work directly with the disease rather than just an animal or commercial cell model. We test our molecules in vitro and link the results to each patient's clinical history (treatment, treatment length, disease stage) to understand what drives the response.”

 

For readers outside the field: how far has rheumatoid arthritis treatment come, and where do new therapies such as CAR-T fit in?

G: Rheumatoid arthritis is treatable but currently not curable. It’s an autoimmune disease that can be kept under control rather than eliminated. Newer biological treatments, including CAR-T cell therapy, are moving closer to a real solution for some patients. CAR-T is already being used in a small number of patients at specialized centers, but selection is strict. Patients go through a series of tests, and eligibility is based on established clinical scores and criteria. Because it’s still experimental for rheumatoid diseases, access and coverage are limited. Currently, our doctors in the institute, have included three or four patients on this therapy but larger studies are still needed.

 

Western blotting is one of the methods in your toolkit. How often do you actually run it, and what role does it play in your experiments?

G: Not every day — more like every three months. We mostly run in vitro studies, and Western blotting is used to corroborate a finding before we move on to the next molecule in a pathway. But when we do run it, it’s rarely a single blot; it’s a full set of experiments with different conditions.

For example, with the cannabinoid receptor work, we look at cannabinoid receptor 1, cannabinoid receptor 2, and a third related receptor, each requiring different conditions and exposure times, since they respond differently to different cytokines and are different sizes. Every receptor essentially needs its own set of optimised conditions.

 

Cannabinoid receptors are membrane proteins. What exactly are you looking for on the blot, and what makes them a difficult target?

G: At this stage, we’re detecting whether the receptors are present and responsive to the inflammatory cytokines we’re using — essentially, whether they are abundant or not in a given patient’s cells. Some receptors are also internalised, taken back up into the cell, which adds another layer of biology to the picture. Higher expression corresponds to a stronger response.

These receptors are around 60 kDa, so medium-sized. For Western blotting they don’t need to be purified; you just need a specific, strong antibody that targets an exposed part of the receptor. Sensitivity is actually the hard part: cannabinoid receptors are highly expressed in the brain but only weakly expressed in the synovial fibroblasts we study, so we need a very sensitive blotting protocol to pick up such a low-abundance target.

In practice, a full experiment — from having the cells ready to a finished blot — typically takes a few weeks, even though the core blotting protocol itself is usually described as taking about two days.

 

Every scientist has an experiment that simply refused to work. What’s yours, and what did it teach you?

G: During an earlier postdoc, I was purifying tubulin from a prokaryotic model, and the protocol worked only once in about ten attempts. Nobody could tell why. Then, at a seminar, a visiting tubulin expert looked at the protocol and immediately asked why Triton, a detergent, was included, since it would prevent the tubule structure from ever forming.

It turned out the protocol had never been questioned; it had simply been inherited from a previous group member. We later suspected that the one successful run was the time the detergent had accidentally been left out. By then, however, my contract was ending and our homemade purification resin had expired, so I never had the chance to confirm it and fix the protocol.

“You shouldn’t just follow the protocol — you have to make sense of it. Why is this ingredient there? Why is this one not there? You should question the protocol.”

 

Phosphorylated proteins are often considered one of the trickiest Western blot targets. Why is that, and what made the biggest difference in your results?

G: Detecting phosphorylated proteins is one of the more difficult Western blot applications, because the total and phosphorylated forms of a protein are the same size and must be distinguished with a phospho-specific antibody. The signal can range from nothing (no activation) to full phosphorylation (strong activation), which makes it a sensitive readout of pathway activity — for example, when working with the JAK-STAT pathway, which is relevant to cancer, metabolism and inflammation research.

For me, the two factors that made the biggest difference were matching the membrane pore size to the protein of interest and using a high-sensitivity chemiluminescent substrate rather than a standard one. Phosphorylated targets are typically low-abundance, so they need longer, more sensitive detection than an abundant housekeeping protein.

 

When an experiment doesn’t work, where do you turn for help?

G: Troubleshooting is mostly trial and error, sometimes supplemented by forums such as ResearchGate. But in my experience, the most reliable channel is contacting the manufacturer’s technical support directly — for example, Cell Signaling Technology for a phospho-STAT3 antibody. Support teams typically ask about the membrane, substrate and detection method you used, then suggest fixes. They can also send a replacement batch or a positive or negative control sample if a batch issue is suspected.

When it comes to antibody reliability, I favour suppliers who publish full validation data and have a track record of citations in peer-reviewed papers, rather than relying on a single image — especially given past controversies over unverified or altered antibody validation images in the industry.

 

What advice would you give a student running their first Western blots — and what mistakes do you see most often?

G: First, that it’s a technique with many sequential steps, and a mistake early on carries through to the end — so it requires sustained attention. It’s tempting to multitask during incubation times (read a paper, get a coffee), but that’s exactly when small mistakes happen, because you lose track of where you were.

The most common mistake I see is assembling the gel and membrane in the wrong order for the transfer, or forgetting to activate the membrane beforehand — either of which means all the preceding effort is wasted. It happens to almost every student at some point, and it’s about focus, not ability.

 

If you could change one thing about the Western blotting workflow, what would it be?

G: I’ve worked with the technique for many years, and several long-standing frustrations have already been addressed by newer products — for example, faster transfer systems that avoid an overnight wait. Anything that shortens incubation, transfer or electrophoresis time without compromising band quality is a clear win.

Overnight steps are still the main bottleneck. Primary antibody incubation is usually done overnight, and an overnight wet transfer — useful because it can be run cold and gives a very clean transfer — means waiting another day before you can even add the antibody. With antibodies that themselves need an overnight incubation, a single blot can stretch over the better part of a week.

 

You recently switched to the VerdiBlot membrane. What difference have you noticed compared with your previous membrane?

G: We’ve used VerdiBlot mainly for phosphorylated-protein detection, and the band definition was good, which made densitometric quantification straightforward. Its pore size sits between the standard 0.2 and 0.45 μm options on the market, so it’s versatile across a wider range of protein sizes.

What surprised me was that the same membrane supports both fluorescence and chemiluminescence detection. In every lab I’d worked in before, we needed two separate membrane types for these two applications.

And then there’s sustainability, which was an unexpected bonus: VerdiBlot is fully biodegradable within three weeks under composting conditions, and its lower environmental impact was another reason for us to adopt it.

“That was the cherry on the cake for making the decision to switch to VerdiBlot.”


 
 
 

Recent Posts

See All

Comments


bottom of page